These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 28467671

  • 1. Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria.
    Church MK, Labeaga L.
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.
    Church MK.
    Expert Opin Drug Saf; 2011 Sep; 10(5):779-93. PubMed ID: 21831011
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
    Hide M, Yagami A, Togawa M, Saito A, Furue M.
    Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans.
    Church MK.
    Inflamm Res; 2011 Dec; 60(12):1107-12. PubMed ID: 21874559
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
    Rodríguez M, Vozmediano V, García-Bea A, Novák Z, Yáñez A, Campo C, Labeaga L.
    Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C, Toubi E, Maurer M, Triggiani M, Ballmer-Weber B, Marsland A, Ferrer M, Knulst A, Giménez-Arnau A.
    Eur J Dermatol; 2017 Feb 01; 27(1):10-19. PubMed ID: 27882879
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Bilastine [Bellozal), oral].
    Duh D, Tanret I.
    J Pharm Belg; 2012 Dec 01; (4):53-4. PubMed ID: 23350212
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
    Wolthers OD.
    Biomed Res Int; 2013 Dec 01; 2013():626837. PubMed ID: 23956994
    [Abstract] [Full Text] [Related]

  • 20. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients.
    Demonte A, Guanti MB, Liberati S, Biffi A, Fernando F, Fainello M, Pepe P.
    Eur Rev Med Pharmacol Sci; 2018 Feb 01; 22(3):820-828. PubMed ID: 29461615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.